| Q38101520 | Antifungal agents in current pediatric practice. |
| Q36967212 | Antifungal agents in neonates: issues and recommendations. |
| Q38015090 | Antifungal therapy in children: an update |
| Q37854725 | Caspofungin therapy in immunocompromised children and neonates |
| Q42272285 | Endemic fungal infections in solid organ transplantation |
| Q43064003 | Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis. |
| Q37159589 | Experiences with the use of caspofungin in paediatric patients |
| Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
| Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
| Q35526999 | Hyperphosphatemia in pediatric oncology patients receiving liposomal amphotericin B |
| Q36822025 | Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome |
| Q46260776 | Pediatric antifungal utilization: new drugs, new trends |
| Q38193337 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. |
| Q36323256 | Posaconazole: a broad-spectrum triazole antifungal |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |